argenx sets October 22 results date as Argenx stock costs EUR 761.20

Published on 10/16/2026 at 10:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

argenx sets its third-quarter update for October 22, 2026. Argenx stock costs EUR 761.20 on October 16, 2026 before results.

Results date and pipeline update

argenx announced its third-quarter results date on October 15, 2026.
Second-quarter product sales reached USD 1.50 billion in 2026.
Argenx stock trades at EUR 761.20 at 10:36 a.m. CEST at Lang & Schwarz on October 16, 2026.
Wells Fargo set a USD 1,356.00 target on October 14, 2026.

Vogelperspektive-Flatlay: Behandschuhte Hände führen Multikanal-Pipette über 96-Well-Mikrotiterplatte mit blauer Flüssigkeit, weißer Labortisch, symmetrische Komposition — Argenx NL0010832176 Mehrkanal-Pipette befüllt von oben eine blaue 96-Well-Platte im Immunologie-Labor sorgfältig, Illustration mit AI erstellt.

argenx stock (ISIN NL0010832176) was at EUR 761.20 at Lang & Schwarz on October 16, 2026 at 10:36 a.m. CEST as the biotechnology company prepared its third-quarter update. According to GlobeNewswire on October 15, 2026, argenx will discuss third-quarter 2026 results and provide a business update on October 22, 2026.

Pipeline setback still shapes the backdrop

The upcoming update follows a mixed clinical picture. On September 29, 2026, argenx presented new VYVGART data covering myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, according to the company's GlobeNewswire.

On October 8, 2026, the company reported that the 126-patient Phase 2 FB102 study in celiac disease met its primary endpoint, while it discontinued the Phase 3 UNITY study in Sjögren's disease after an interim analysis. The same release said the FB102 result had a p-value of 0.0176 and that the FDA had granted Fast Track designation.

What will the October 22 update test?

For investors, Vyvgart sales and pipeline timing are the central figures. Argenx generated USD 1.50 billion in global product net sales in the second quarter of 2026, up 60 percent year over year and 17 percent from the first quarter, according to Zacks on October 9, 2026. The October 22 conference call is scheduled for 2:30 p.m. CET and will add management commentary to the financial release.

Analyst targets reflect competing signals

Wells Fargo raised its target from USD 1,355.00 to USD 1,356.00 and maintained an overweight rating on October 14, 2026, according to Markets Insider. Oppenheimer had lowered its target from USD 1,100.00 to USD 1,038.00 on October 12, 2026, while keeping an outperform rating, according to MarketBeat.

Stock holds above its annual low

argenx had a market capitalization of USD 52.3 billion and a 52-week range of USD 661.85 to USD 1,072.75 in the finance snapshot dated October 15, 2026. The October 16 euro quote therefore sits above the lower end of that range when viewed alongside the primary-market data.

argenx was trading at EUR 761.20 at Lang & Schwarz on October 16, 2026 at 10:36 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of argenx stock.